TY - JOUR
T1 - CHOP versus m-BACOD in Non-Hodgkin's Lymphoma
AU - Hryniuk, W.
AU - Gordon, L. I.
AU - Harrington, D.
AU - Andersen, J.
PY - 1993/2/25
Y1 - 1993/2/25
N2 - To the Editor: The results of a randomized trial reported by Gordon et al. (Nov. 5 issue)1 indicate that a chemotherapeutic regimen containing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and one containing bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, methotrexate, and leucovorin (m-BACOD) were equivalent in their activity against diffuse advanced non-Hodgkin's lymphoma but that m-BACOD was more toxic. The authors stated that “the normalized dose intensity with CHOP was higher than that with m-BACOD… even though the prescribed doses of both cyclophosphamide and doxorubicin were higher in the CHOP regimen.” Although the authors then state that “the actual…
AB - To the Editor: The results of a randomized trial reported by Gordon et al. (Nov. 5 issue)1 indicate that a chemotherapeutic regimen containing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and one containing bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, methotrexate, and leucovorin (m-BACOD) were equivalent in their activity against diffuse advanced non-Hodgkin's lymphoma but that m-BACOD was more toxic. The authors stated that “the normalized dose intensity with CHOP was higher than that with m-BACOD… even though the prescribed doses of both cyclophosphamide and doxorubicin were higher in the CHOP regimen.” Although the authors then state that “the actual…
UR - http://www.scopus.com/inward/record.url?scp=0027518259&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027518259&partnerID=8YFLogxK
U2 - 10.1056/NEJM199302253280813
DO - 10.1056/NEJM199302253280813
M3 - Letter
C2 - 7678920
AN - SCOPUS:0027518259
SN - 0028-4793
VL - 328
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 8
ER -